Semaglutide: A Comprehensive Pharmacological and Clinical Review

1. Introduction to Semaglutide

1.1. Overview and Drug Class

Semaglutide is a prominent therapeutic agent classified as a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA).[1] It is a synthetic peptide analogue of human GLP-1, sharing 94% sequence homology with the native hormone, and has been engineered for an extended pharmacokinetic profile and enhanced therapeutic efficacy.[1] GLP-1 RAs mimic the action of the endogenous incretin hormone GLP-1, which plays a crucial role in glucose homeostasis and appetite regulation. This class of drugs has revolutionized the management of type 2 diabetes mellitus and, more recently, obesity and related cardiometabolic conditions.

1.2. Therapeutic Significance and Key Indications

Semaglutide was initially developed and approved for the treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.[1] Its therapeutic applications have since expanded significantly. It is now also indicated for chronic weight management in adults and adolescents (aged 12 years and older) with obesity or those who are overweight and have at least one weight-related comorbidity.[1]

Recognizing its broader metabolic benefits, regulatory agencies have further approved semaglutide to reduce the risk of major adverse cardiovascular events (MACE), such as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. This indication applies to adults with established cardiovascular disease (CVD) who are also living with either obesity or overweight, and to adults with T2DM and known heart disease.[1] Most recently, its therapeutic scope was broadened to include the reduction of risk of kidney disease progression, encompassing events like sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease (ESKD), and cardiovascular or renal death in adults with T2DM and chronic kidney disease (CKD).[7]

The evolution of semaglutide's indications from a glucose-lowering agent to a therapy with proven benefits in weight management, cardiovascular risk reduction, and renal protection underscores a significant trend in modern pharmacology. The initial focus on glycemic control in T2DM trials, such as the SUSTAIN program, consistently revealed weight loss as a notable secondary benefit.[10] This observation paved the way for dedicated weight management trials (e.g., the STEP program), which confirmed substantial efficacy in this area.[12] Subsequently, large-scale cardiovascular outcome trials (CVOTs) like SUSTAIN-6, PIONEER-6, and particularly the SELECT trial (which included non-diabetic individuals), established its cardiovascular protective effects.[5] The FLOW trial further solidified its role in nephroprotection among T2DM patients with CKD.[8] This trajectory from a single metabolic indication to multiple, interconnected cardiometabolic and renal benefits highlights a deeper understanding of the systemic impact of GLP-1 agonism and the interconnectedness of these chronic conditions. This success is likely to spur further investigation into GLP-1 RAs for an even wider array of metabolic and cardiovascular diseases, potentially reshaping treatment paradigms.

1.3. Development and Commercialization

Semaglutide was developed and is marketed by Novo Nordisk.[1] It is available under distinct brand names corresponding to its formulation and primary indication:

• Ozempic®: A subcutaneous injection primarily for T2DM, cardiovascular risk reduction in T2DM patients with CVD, and risk reduction of kidney disease progression in T2DM patients with CKD.[7]
• Rybelsus®: An oral tablet formulation for the treatment of T2DM.[19]
• Wegovy®: A subcutaneous injection, typically at a higher dose than Ozempic®, for chronic weight management and cardiovascular risk reduction in adults with established CVD and either obesity or overweight.[4]

1.4. DrugBank ID and CAS Number

For precise identification in pharmacological databases and scientific literature, semaglutide is assigned:

• DrugBank ID: DB13928 [1]
• CAS Number: 910463-68-2 [1]

1.5. Scope of the Report

This report aims to provide a comprehensive pharmacological and clinical overview of semaglutide. It will detail its chemical characteristics, formulations, mechanism of action, and pharmacokinetic profile. Furthermore, it will extensively review its clinical efficacy across approved indications, drawing upon data from major clinical trial programs. The safety and tolerability profile, including common and serious adverse effects, contraindications, and drug interactions, will be thoroughly discussed. Finally, the report will cover the regulatory landscape, including approvals by major health authorities, and provide a comparative context within the GLP-1 RA class.

2. Chemical Characteristics and Formulations

2.1. Molecular Structure and Properties

Semaglutide is a synthetic peptide analogue of human glucagon-like peptide-1 (GLP-1), specifically GLP-1-(7-37), with 94% amino acid sequence homology to the native human hormone.[1] It is a linear polypeptide composed of 31 amino acids.[26] The molecular formula of semaglutide is C187​H291​N45​O59​, and its molar mass is 4113.641 g·mol⁻¹.[1] Its peptide nature inherently makes it susceptible to enzymatic degradation and poses challenges for oral administration, necessitating strategic molecular modifications and formulation technologies for therapeutic use.

2.2. Key Structural Modifications for Enhanced Pharmacokinetics

To overcome the short half-life of native GLP-1 and enable less frequent dosing, semaglutide incorporates several critical structural modifications:

• DPP-4 Resistance: The alanine residue at position 8 of native GLP-1 (corresponding to position 2 in semaglutide's modified sequence, as the first six N-terminal amino acids of GLP-1 are absent) is substituted with 2-aminoisobutyric acid (Aib).[1] This substitution confers resistance to degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which rapidly inactivates native GLP-1. This modification is fundamental to prolonging the molecule's systemic exposure.
• Albumin Binding Moiety: At position 20 (corresponding to lysine at position 26 in native GLP-1), the lysine residue is acylated.[1] A C18 fatty diacid (stearic diacid) is attached via a hydrophilic spacer (linker). This modification facilitates strong, non-covalent, and reversible binding to serum albumin.[1] Albumin binding serves as a protective mechanism, shielding semaglutide from enzymatic degradation and significantly reducing its renal clearance, thereby dramatically extending its plasma half-life. The specific structure of this linker is detailed in patent EP1863839B1.[31]
• Modification at Position 34: To ensure site-specific acylation and prevent the attachment of more than one fatty diacid moiety, the lysine residue at position 34 of native GLP-1 (corresponding to position 28 in semaglutide) is substituted with arginine.[3]

These engineered modifications—Aib substitution for DPP-4 resistance and fatty acid acylation for albumin binding—work synergistically. Native GLP-1 is rapidly cleared due to DPP-4 degradation and renal filtration.[28] The Aib modification directly blocks DPP-4 cleavage.[1] The Lys20 acylation promotes robust albumin binding, creating a circulating reservoir that protects semaglutide from other enzymatic degradation and slows renal filtration due to the large size of the albumin-semaglutide complex.[25] This results in a significantly prolonged elimination half-life of approximately one week, making convenient once-weekly subcutaneous dosing possible and improving patient adherence compared to older, more frequently administered GLP-1 RAs. This approach reflects a broader strategy in peptide drug development aimed at creating long-acting formulations.

2.3. Formulations

Semaglutide is available in two distinct types of formulations: subcutaneous injection and oral tablets.

• Subcutaneous Injection (Ozempic®, Wegovy®):
• Ozempic®: Marketed for T2DM and associated cardiovascular/renal risk reduction, Ozempic® is available in pre-filled, multi-dose pens delivering 0.25 mg (initial dose), 0.5 mg, 1 mg, or 2 mg of semaglutide per injection.[17] The solution is clear, colorless, and isotonic with a pH of 7.4.[30]
• Wegovy®: Marketed for chronic weight management and cardiovascular risk reduction in eligible individuals, Wegovy® is available in pre-filled, single-dose pens delivering 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg of semaglutide per injection.[4] The solution characteristics are similar to Ozempic®.[35] The subcutaneous route allows for direct systemic absorption, bypassing first-pass metabolism, which is advantageous for peptide-based therapeutics.
• Oral Tablets (Rybelsus®):
• Rybelsus® represents a significant innovation in peptide drug delivery, offering the first oral GLP-1 RA. It is available in two formulations: Formulation R1 (tablets of 3 mg, 7 mg, and 14 mg) and Formulation R2 (tablets of 1.5 mg, 4 mg, and 9 mg).[19]
• To overcome the challenges of oral peptide administration (enzymatic degradation and poor membrane permeability), Rybelsus® is co-formulated with an absorption enhancer, Salcaprozate Sodium (SNAC) (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) at a dose of 300 mg per tablet.[25]
• SNAC facilitates the gastric absorption of semaglutide through several mechanisms:

1. Local pH Buffering: SNAC creates a localized increase in gastric pH, which protects semaglutide from degradation by the acidic environment and the proteolytic enzyme pepsin.[33]
2. Promotion of Monomerization: SNAC helps to keep semaglutide in its monomeric form, which is more readily absorbed.[41]
3. Enhanced Transcellular Absorption: SNAC transiently and reversibly increases the permeability of the gastric mucosal cells, allowing semaglutide to pass across the cell membrane into the systemic circulation.[33] This absorption primarily occurs in the stomach, unlike most orally administered drugs which are absorbed in the small intestine.[41] The development of an oral formulation using SNAC technology is a pivotal advancement, expanding patient choice and potentially improving adherence for individuals averse to injections. However, the need for two distinct oral formulations (R1 and R2) with different strengths suggests ongoing efforts to optimize this delivery system and manage the inherent variability in oral peptide absorption.

3. Mechanism of Action

3.1. GLP-1 Receptor Agonism

Semaglutide exerts its therapeutic effects by acting as a selective GLP-1 receptor agonist.[1] It binds to and activates GLP-1 receptors, which are G protein-coupled receptors found on the surface of various cell types throughout the body. These include pancreatic beta-cells and alpha-cells, neurons in the brain (particularly in the hypothalamus and brainstem), cells in the gastrointestinal tract, heart, and vasculature.[43] This widespread receptor distribution accounts for the diverse physiological actions of semaglutide. While its affinity for the GLP-1 receptor is slightly lower than that of liraglutide, another GLP-1 RA, this is effectively compensated by its enhanced binding to serum albumin, which improves its resistance to metabolic degradation and prolongs its duration of action.[29]

3.2. Pancreatic Effects (Glucose Homeostasis)

Semaglutide's primary actions on the pancreas are crucial for its glucose-lowering effects in type 2 diabetes:

• Glucose-Dependent Insulin Secretion: Semaglutide stimulates the secretion of insulin from pancreatic beta-cells in a manner that is dependent on blood glucose concentrations.[1] This means that insulin release is augmented primarily when blood glucose levels are elevated (e.g., after a meal), thereby reducing the risk of hypoglycemia that can be associated with other insulin secretagogues that act independently of glucose levels.
• Glucagon Suppression: It inhibits the secretion of glucagon from pancreatic alpha-cells, particularly in the postprandial state.[1] Glucagon normally acts to increase hepatic glucose production; its suppression by semaglutide thus contributes to lower blood glucose levels. This effect is also largely glucose-dependent, further minimizing hypoglycemia risk.
• Beta-Cell Function and Proliferation: There is some evidence suggesting that GLP-1 RAs, including semaglutide, may have beneficial effects on pancreatic beta-cell health, potentially enhancing their function and promoting their proliferation, although the clinical significance of this in humans is still under investigation.[1]

The glucose-dependent nature of semaglutide's actions on insulin and glucagon secretion is a key safety feature. By primarily influencing these hormones when glucose levels are high, it inherently limits the potential for causing inappropriately low blood sugar levels, especially when used as monotherapy. This contrasts with older classes of diabetes medications, such as sulfonylureas, which can induce hypoglycemia regardless of blood glucose levels.

3.3. Extra-Pancreatic Effects (Weight Management and Other Benefits)

Beyond its direct effects on the pancreas, semaglutide influences several other physiological processes that contribute to its efficacy in weight management and its cardiovascular and renal protective benefits:

• Delayed Gastric Emptying: Semaglutide slows the rate at which food is emptied from the stomach into the small intestine.[1] This delay in gastric emptying contributes to a prolonged feeling of fullness and satiety after meals, which can lead to reduced food intake. This mechanism also has implications for the absorption of concomitantly administered oral medications, as it can alter their absorption rate and potentially their peak concentrations.[30]
• Appetite Regulation (Central Effects): Semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors located in key areas of the brain involved in appetite control, such as the hypothalamus and brainstem.[43] This central action leads to a reduction in appetite, decreased hunger signals, diminished food cravings (particularly for high-fat foods), and an enhanced sensation of satiety.[1] These effects collectively contribute to a reduction in overall caloric intake and are a primary driver of its weight loss efficacy.
• Increased Energy Expenditure and Lipid Metabolism: Some preclinical and clinical evidence suggests that semaglutide may also influence energy expenditure, potentially increasing it, and promote the burning of fat.[45] It has also been associated with favorable changes in lipid profiles, including reductions in triglycerides and LDL cholesterol.
• Cardiovascular Effects: The cardiovascular benefits observed with semaglutide are thought to be multifactorial. Beyond the positive impact of weight loss and improved glycemic control, potential direct mechanisms include reduction of systemic inflammation, improvement in endothelial function, beneficial effects on blood pressure, and potentially plaque stabilization within blood vessels.[5]
• Renal Effects: Similarly, the renoprotective effects are likely due to a combination of improved glycemic and blood pressure control, weight reduction, and potentially direct effects on the kidneys, such as reducing intraglomerular pressure and inflammation.[25]

The interconnectedness of these mechanisms is noteworthy. For instance, the delayed gastric emptying not only promotes satiety, aiding weight loss, but also smooths postprandial glucose excursions, benefiting glycemic control. However, as mentioned, this same effect necessitates careful consideration of the timing and absorption of other oral medications. This illustrates how a single pharmacological action can have multiple therapeutic consequences as well as clinical management implications.

4. Pharmacokinetics

The pharmacokinetic profile of semaglutide has been extensively studied for both its subcutaneous and oral formulations. Key modifications to the native GLP-1 structure, particularly the acylation with a fatty diacid moiety leading to strong albumin binding, and the substitution conferring DPP-4 resistance, are fundamental to its prolonged half-life.

4.1. Subcutaneous Semaglutide (Ozempic®, Wegovy®)

• Absorption:
• Following subcutaneous administration, semaglutide exhibits high absolute bioavailability, estimated at 89%.[28]
• The maximum plasma concentration (Tmax) is typically reached within 1 to 3 days post-dose.[28]
• Steady-state concentrations are achieved after 4 to 5 weeks of consistent once-weekly administration.[28]
• Semaglutide exposure, as measured by area under the curve (AUC) and maximum concentration (Cmax), increases in a dose-proportional manner for approved therapeutic doses (e.g., 0.5 mg, 1 mg, and 2 mg).[30]
• The site of subcutaneous injection (abdomen, thigh, or upper arm) does not clinically significantly impact the absorption or overall exposure of semaglutide.[18]
• Distribution:
• The mean volume of distribution (Vd​) of semaglutide following subcutaneous administration in patients with T2DM is approximately 12.5 liters.[30]
• A critical pharmacokinetic feature is its extensive binding to plasma albumin, exceeding 99%.[28] This high degree of protein binding is a primary contributor to its long duration of action and stability in circulation.
• Metabolism:
• Semaglutide is metabolized primarily through proteolytic cleavage of its peptide backbone and subsequent beta-oxidation of the C18 fatty diacid side chain.[25]
• The enzyme neutral endopeptidase (NEP) is anticipated to play a role in its metabolism.[28]
• While semaglutide is engineered for resistance to DPP-4, this enzyme can still contribute to some degree of N-terminal truncation, albeit at a much slower rate than for native GLP-1.[28]
• Metabolism is not confined to a specific organ (e.g., liver or kidney) but appears to occur more generally across tissues.[25]
• Elimination:
• The elimination half-life (t1/2​) of subcutaneous semaglutide is remarkably long, approximately 1 week (equivalent to 165-184 hours).[1]
• The clearance (CL) of semaglutide in patients with T2DM is low, approximately 0.05 L/h.[30]
• Metabolites of semaglutide are primarily excreted via urine (approximately two-thirds) and feces (approximately one-third).[30]
• Only a small fraction (approximately 3%) of the absorbed dose is excreted as intact semaglutide in the urine.[30]
• Due to its extended half-life, semaglutide remains in the systemic circulation for approximately 5 weeks after the last dose.[30]

The extensive albumin binding is a direct cause of this prolonged elimination half-life. By binding to albumin, semaglutide is protected from rapid enzymatic degradation by various proteases and is too large for efficient glomerular filtration by the kidneys, thus significantly slowing its clearance from the body.[25] This pharmacokinetic property is the cornerstone of the once-weekly dosing regimen for Ozempic® and Wegovy®, enhancing patient convenience and adherence.

4.2. Oral Semaglutide (Rybelsus®)

• Absorption:
• Rybelsus® is co-formulated with the absorption enhancer salcaprozate sodium (SNAC) (300 mg), which is crucial for its oral bioavailability.[25] SNAC facilitates the absorption of semaglutide primarily in the stomach, a unique site for peptide absorption.[41]
• The absolute bioavailability of oral semaglutide is low, estimated to be between 0.4% and 1%.[28] This low bioavailability necessitates higher milligram doses for the oral formulation compared to the subcutaneous one to achieve comparable systemic exposures.
• Maximum plasma concentration (Tmax) is typically reached approximately 1 hour after oral administration under fasting conditions.[28]
• Steady-state plasma concentrations are achieved after 4 to 5 weeks of once-daily administration.[28]
• The absorption of oral semaglutide is highly influenced by administration conditions:
• It must be taken on an empty stomach, at least 30 minutes before the first food, beverage, or other oral medications of the day.[19]
• It should be taken with no more than 4 ounces (120 mL) of plain water. Taking it with food, other beverages, or other oral medications, or waiting less than 30 minutes before ingesting these, will significantly lessen its effect by decreasing absorption.[42]
• Conversely, waiting more than 30 minutes after taking Rybelsus® before eating may increase its absorption.[42] The pharmacokinetics of oral semaglutide underscore the challenges inherent in oral peptide delivery. SNAC technology provides an innovative solution, but the resulting absorption is still sensitive to administration protocols. The low bioavailability and high dependency on strict fasting and water volume conditions highlight the delicate balance SNAC creates to facilitate gastric absorption. This makes patient education and adherence to administration instructions paramount for achieving therapeutic efficacy with Rybelsus®.
• Distribution:
• The estimated volume of distribution (Vd​) after oral administration in healthy subjects is approximately 8 L.[42]
• Similar to the subcutaneous formulation, oral semaglutide is extensively bound to plasma albumin (>99%).[28]
• Metabolism:
• The metabolic pathway is consistent with that of subcutaneous semaglutide, involving proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid side chain.[25]
• Elimination:
• The elimination half-life (t1/2​) of oral semaglutide is also approximately 1 week.[42]
• Clearance in healthy subjects is approximately 0.04 L/h.[42]
• Metabolites are primarily excreted via urine and feces, with about 3% of the absorbed dose excreted as intact semaglutide in the urine.[42]

4.3. Special Populations (General Findings for Semaglutide)

Pharmacokinetic studies have generally shown that no clinically relevant dose adjustments are typically required for semaglutide (both subcutaneous and oral formulations) based on age (including geriatric patients), race, ethnicity, sex, or body weight.[25] Although body weight may have some influence on semaglutide exposure, this has not necessitated routine dose adjustments, though further studies may clarify this aspect.[25]

For patients with renal or hepatic impairment, dose adjustments are generally not needed for subcutaneous semaglutide, even in patients with end-stage renal disease (ESRD).[25] For oral semaglutide (Rybelsus®), while no dose adjustment is typically recommended for mild to moderate renal impairment, caution is advised in severe renal impairment due to limited data. Importantly, if severe gastrointestinal adverse reactions occur in patients with renal impairment, renal function should be monitored due to the risk of dehydration-induced acute kidney injury.[49] Similarly, hepatic impairment does not generally require dose adjustment for either formulation.[25] This consistent pharmacokinetic profile across diverse patient populations simplifies dosing strategies but underscores the need for vigilance regarding renal function in specific situations with the oral form.

The following table summarizes key pharmacokinetic parameters for the different formulations of semaglutide:

Table 1: Comparative Pharmacokinetic Parameters of Semaglutide Formulations

Parameter	Ozempic®/Wegovy® (Subcutaneous)	Rybelsus® (Oral)
Absolute Bioavailability	89% 28	~0.4% - 1% 28
Time to Max. Conc. (Tmax)	1 - 3 days 28	~1 hour (fasting) 28
Time to Steady State	4 - 5 weeks (once-weekly) 28	4 - 5 weeks (once-daily) 28
Volume of Distribution (Vd)	~12.5 L (T2DM patients) 30	~8 L (healthy subjects) 42
Plasma Protein Binding	>99% (to albumin) 28	>99% (to albumin) 28
Elimination Half-life (t1/2​)	~1 week 1	~1 week 42
Clearance (CL)	~0.05 L/h (T2DM patients) 30	~0.04 L/h (healthy subjects) 42
Primary Metabolism Route	Proteolytic cleavage, β-oxidation 25	Proteolytic cleavage, β-oxidation 25
Primary Excretion Route	Metabolites in urine and feces 30	Metabolites in urine and feces 42

5. Clinical Efficacy

The clinical development of semaglutide has been extensive, encompassing large-scale trial programs—SUSTAIN and PIONEER for type 2 diabetes, STEP for obesity, and the cardiovascular outcomes trials SELECT and FLOW. These programs have established its efficacy across its approved indications.

5.1. Type 2 Diabetes Mellitus (T2DM)

Ozempic® (Subcutaneous Semaglutide):

The SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) clinical trial program, comprising multiple global phase 3 trials (SUSTAIN 1-11 and Japan-specific studies), has robustly demonstrated the efficacy of once-weekly subcutaneous semaglutide in improving glycemic control and promoting weight loss in adults with T2DM.10

• Glycated Hemoglobin (HbA1c) Reduction: Across the SUSTAIN trials, Ozempic® consistently achieved statistically significant and clinically meaningful reductions in HbA1c compared to placebo and active comparators, including sitagliptin, exenatide extended-release (ER), insulin glargine, and dulaglutide. Reductions typically ranged from 1.0% to 1.8% for the 0.5 mg dose and 1.3% to 2.2% for the 1 mg and 2 mg doses, depending on baseline HbA1c and background therapy.[10] For instance, in SUSTAIN 1 (monotherapy), Ozempic® 0.5 mg and 1 mg reduced mean HbA1c by 1.4% and 1.6%, respectively, from a baseline of ~8.1%, compared to a 0.1% reduction with placebo over 30 weeks.[53] In SUSTAIN 7, a head-to-head trial, semaglutide 0.5 mg and 1.0 mg demonstrated superior HbA1c reductions (1.5% and 1.8%, respectively) compared to dulaglutide 0.75 mg and 1.5 mg (1.1% and 1.4%, respectively) over 40 weeks.[55] The SUSTAIN FORTE trial showed that semaglutide 2.0 mg provided an additional 0.2% HbA1c reduction compared to semaglutide 1.0 mg.[53]
• Body Weight Reduction: A consistent secondary benefit observed across the SUSTAIN program was significant weight loss. Patients treated with Ozempic® experienced mean weight reductions ranging from approximately 3.5 kg to 6.9 kg, which were generally superior to those seen with comparators.[10] In SUSTAIN 1, weight loss was 3.8 kg with 0.5 mg and 4.7 kg with 1 mg, versus 1.2 kg with placebo.[53]

Rybelsus® (Oral Semaglutide):

The PIONEER (Peptide InnOvatioN for Early diabEtes tReatment) clinical trial program established the efficacy of once-daily oral semaglutide in adults with T2DM.49

• HbA1c Reduction: Rybelsus® demonstrated superior HbA1c reductions compared to placebo and active comparators such as empagliflozin and sitagliptin, and non-inferiority to liraglutide. Mean HbA1c reductions with Rybelsus® 7 mg and 14 mg typically ranged from 1.0% to 1.4% from baseline.[49] In PIONEER 1 (monotherapy), Rybelsus® 7 mg and 14 mg reduced HbA1c by 1.2% and 1.4%, respectively, from a baseline of 8.0%, compared to a 0.3% reduction with placebo over 26 weeks.[49]
• Body Weight Reduction: Rybelsus® also led to statistically significant weight loss compared to placebo and some active comparators. Mean weight reductions typically ranged from 2.2 kg to 4.4 kg with the 7 mg and 14 mg doses.[49] In PIONEER 1, weight loss was 2.3 kg with 7 mg and 3.7 kg with 14 mg, versus 1.4 kg with placebo.[49]

5.2. Chronic Weight Management

Wegovy® (Subcutaneous Semaglutide 2.4 mg):

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program investigated the efficacy of once-weekly subcutaneous semaglutide 2.4 mg for chronic weight management in adults and adolescents with obesity or overweight with at least one weight-related comorbidity.12

• Weight Loss in Adults: Wegovy® demonstrated substantial and sustained weight loss.
• In STEP 1, adults without T2DM achieved a mean weight loss of 14.9% from baseline with Wegovy® versus 2.4% with placebo over 68 weeks.[23]
• In STEP 2, adults with T2DM (a population often more resistant to weight loss) achieved a mean weight loss of 9.6% with Wegovy® versus 3.4% with placebo over 68 weeks.[61]
• A significant proportion of participants achieved clinically meaningful weight loss thresholds: in STEP 1, 83.5% lost ≥5% body weight, 66.1% lost ≥10%, and 47.9% lost ≥15% with Wegovy®, compared to 31.1%, 12.0%, and 4.8% with placebo, respectively.[63] Approximately one-third of adults in STEP 1 achieved ≥20% weight loss.[23]
• The STEP UP trial, evaluating a higher dose of semaglutide (7.2 mg), showed even greater mean weight loss of 20.7% in adherent individuals, compared to 17.5% with the 2.4 mg dose and 2.4% with placebo over 72 weeks.[12]
• Weight Loss in Adolescents (≥12 years): In the STEP TEENS trial, adolescents treated with Wegovy® experienced a mean reduction in BMI of 16.1%, compared to a 0.6% increase with placebo over 68 weeks.[63]
• Improvements in Cardiometabolic Risk Factors: Alongside weight loss, Wegovy® treatment led to improvements in waist circumference, blood pressure, lipid profiles, and measures of physical function and quality of life.[23]

5.3. Cardiovascular Risk Reduction

The cardiovascular benefits of semaglutide have been established in dedicated CVOTs for its different formulations.

• Ozempic® (Subcutaneous Semaglutide):
• The SUSTAIN-6 trial (NCT01720446) enrolled 3,297 adults with T2DM and high cardiovascular risk.[14] Ozempic® (0.5 mg or 1 mg weekly) significantly reduced the risk of the primary composite MACE outcome (CV death, non-fatal MI, or non-fatal stroke) by 26% compared to placebo over a median follow-up of 2.1 years (Hazard Ratio 0.74; 95% Confidence Interval [CI] 0.58-0.95; P<0.001 for non-inferiority; P=0.02 for superiority).[14] The benefit was primarily driven by significant reductions in non-fatal stroke (39%) and non-fatal MI (26%), with no significant difference in CV death alone.[14]
• Rybelsus® (Oral Semaglutide):
• The PIONEER 6 trial (NCT02692716) assessed the cardiovascular safety of oral semaglutide in 3,183 adults with T2DM and high CV risk.[15] Over a median follow-up of 15.9 months, Rybelsus® demonstrated non-inferiority to placebo for MACE (HR 0.79; 95% CI 0.57-1.11; P<0.001 for non-inferiority).[15] While the trial was not powered for superiority, there was a nominally significant 51% reduction in the risk of CV death (HR 0.49; 95% CI 0.27-0.92) and a 20% reduction in all-cause mortality (HR 0.80; 95% CI 0.67-0.95) with Rybelsus®.[15]
• Wegovy® (Subcutaneous Semaglutide 2.4 mg):
• The SELECT trial (NCT03574597) was a landmark study involving 17,604 adults with overweight or obesity (BMI ≥27 kg/m²) and established CVD without diabetes.[5] Wegovy® 2.4 mg once weekly significantly reduced the risk of MACE by 20% compared to placebo when added to standard of care, over a mean follow-up of 39.8 months (HR 0.80; 95% CI 0.72-0.90; P<0.001).[68] Notably, cardiovascular benefits were observed early, within the first 3 to 6 months of treatment, potentially preceding maximal weight loss, suggesting mechanisms beyond weight reduction alone might contribute.[5]

5.4. Chronic Kidney Disease (CKD) in Type 2 Diabetes

• Ozempic® (Subcutaneous Semaglutide 1 mg):
• The FLOW trial (NCT03819153) evaluated the effects of Ozempic® 1 mg once weekly versus placebo in 3,533 adults with T2DM and CKD (defined by eGFR and albuminuria criteria).[8] Ozempic® significantly reduced the risk of the primary composite kidney disease endpoint (kidney failure, or death from renal or cardiovascular causes) by 24% compared to placebo (HR 0.76; 95% CI 0.66-0.88; P=0.0003) over a median follow-up of 3.4 years.[8]
• Ozempic® also demonstrated an 18% reduction in MACE and a 20% reduction in all-cause mortality in this high-risk population.[53]

The collective evidence from these extensive trial programs highlights semaglutide's profound and broad cardiometabolic-renal benefits. Initially recognized for robust glucose lowering and weight loss, its role has expanded to include significant cardiovascular risk reduction, even in individuals without diabetes, and crucial renal protection for patients with T2DM and CKD. While direct pleiotropic effects on the cardiovascular and renal systems are likely, particularly given early CV benefits seen in the SELECT trial before maximal weight loss [5], the substantial and sustained weight loss achieved with semaglutide is undoubtedly a major contributor to these long-term organ-protective outcomes. Weight loss itself ameliorates numerous risk factors such as hypertension, dyslipidemia, and insulin resistance, all of which impact cardiovascular and renal health.[45] This positions semaglutide as a foundational therapy in the management of a wide spectrum of interconnected metabolic disorders.

Table 2: Summary of Key Efficacy Outcomes from Major Semaglutide Clinical Trial Programs

Trial Program (Key Trial)	Brand Name (Formulation)	Patient Population	Comparator(s)	Primary Endpoint(s)	Key Semaglutide Result (vs. Comparator/Placebo)	Mean $\Delta$HbA1c (Semaglutide vs. Comparator)	Mean $\Delta$Body Weight (Semaglutide vs. Comparator)
SUSTAIN-1 53	Ozempic® (SubQ)	T2DM, diet & exercise	Placebo	Change in HbA1c at 30 wk	Superior HbA1c & weight reduction	0.5mg: -1.2%; 1mg: -1.4%	0.5mg: -2.6 kg; 1mg: -3.5 kg
SUSTAIN-6 14	Ozempic® (SubQ)	T2DM & high CV risk	Placebo	Time to first MACE	26% MACE risk reduction (HR 0.74)	-	-
PIONEER 1 49	Rybelsus® (Oral)	T2DM, diet & exercise	Placebo	Change in HbA1c at 26 wk	Superior HbA1c & weight reduction (14mg)	7mg: -0.9%; 14mg: -1.1%	7mg: -0.9 kg; 14mg: -2.3 kg
PIONEER 6 15	Rybelsus® (Oral)	T2DM & high CV risk	Placebo	Time to first MACE	Non-inferior for MACE (HR 0.79)	-	-
STEP 1 23	Wegovy® (SubQ 2.4mg)	Obesity/Overweight (no T2DM)	Placebo	% change in body weight at 68 wk	-12.4% greater weight loss	N/A	-12.4% (approx. -12.7 kg)
STEP 2 61	Wegovy® (SubQ 2.4mg)	Obesity/Overweight & T2DM	Placebo	% change in body weight at 68 wk	-6.2% greater weight loss	Significant improvement	-6.2% (approx. -6.2 kg)
SELECT 68	Wegovy® (SubQ 2.4mg)	Overweight/Obesity & CVD (no T2DM)	Placebo	Time to first MACE	20% MACE risk reduction (HR 0.80)	N/A	Significant weight loss
FLOW 8	Ozempic® (SubQ 1mg)	T2DM & CKD	Placebo	Time to first major kidney disease event or CV/renal death	24% kidney events risk reduction (HR 0.76)	-	-

MACE: Major Adverse Cardiovascular Event (typically CV death, non-fatal MI, non-fatal stroke). Results are approximate and reflect primary findings; refer to specific trial publications for full details and statistical significance.

6. Safety and Tolerability Profile

The safety profile of semaglutide has been extensively evaluated across its clinical trial programs. While generally well-tolerated, particularly with gradual dose escalation, it is associated with characteristic adverse effects and carries important warnings and contraindications.

6.1. Common Adverse Effects

The most frequently reported adverse effects associated with semaglutide are gastrointestinal in nature. These are typically mild to moderate in severity and often transient, occurring most commonly during the initial phase of treatment and dose escalation, and tending to diminish over time.[1]

• Gastrointestinal Effects: Nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, dyspepsia, eructation, flatulence, gastroenteritis, and gastroesophageal reflux disease (GERD) are commonly reported.[1]
• Other Common Effects: Headache, fatigue, and dizziness have also been reported.[1] For subcutaneous formulations (Ozempic®, Wegovy®), injection site reactions (e.g., redness, itching, swelling) may occur but are generally mild and transient.[53]

The prevalence of GI adverse events underscores the importance of the recommended gradual dose titration schedules for all semaglutide products. This approach allows the body to adapt to the medication, potentially reducing the incidence and severity of these common side effects and thereby improving patient adherence to long-term therapy.

6.2. Serious Adverse Effects and Boxed Warning

Semaglutide is associated with several serious adverse effects and carries a boxed warning regarding the risk of thyroid C-cell tumors.

• Risk of Thyroid C-Cell Tumors (Boxed Warning):
• All semaglutide formulations (Ozempic®, Rybelsus®, Wegovy®) carry a boxed warning regarding the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC).[8]
• This warning is based on findings in rodent studies where semaglutide caused a dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors at clinically relevant exposures. The human relevance of these findings is unknown, as MTC is a rare cancer in humans.[88]
• Semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[8]
• Patients should be counseled about the potential risk and informed of symptoms suggestive of thyroid tumors (e.g., a neck mass, dysphagia, dyspnea, persistent hoarseness).[9] Routine monitoring with serum calcitonin or thyroid ultrasound is of uncertain value for early MTC detection in this context.[49]
• Acute Pancreatitis:
• Cases of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, have been reported with GLP-1 RAs, including semaglutide.[1]
• While clinical trials have not consistently demonstrated an increased risk compared to placebo, post-marketing surveillance has identified cases.[79] The underlying mechanism is not fully understood but may involve alterations in pancreatic enzyme levels or ductal cell changes in susceptible individuals.[80]
• Patients should be monitored for signs and symptoms (e.g., persistent severe abdominal pain, often radiating to the back, with or without vomiting). If pancreatitis is suspected, semaglutide should be discontinued immediately, and appropriate medical management initiated.[8]
• Semaglutide has not been studied in patients with a prior history of pancreatitis.[34]
• Diabetic Retinopathy Complications:
• In patients with T2DM, particularly those with pre-existing diabetic retinopathy, rapid improvement in glycemic control has been associated with a temporary worsening of diabetic retinopathy.[9] The SUSTAIN-6 trial reported a higher incidence of diabetic retinopathy complications in patients treated with Ozempic® (3.0%) compared to placebo (1.8%).[53]
• Patients with a history of diabetic retinopathy should be monitored for progression of this condition when treated with semaglutide.[49]
• Hypoglycemia:
• The risk of hypoglycemia with semaglutide monotherapy or in combination with metformin is generally low due to its glucose-dependent mechanism of insulin secretion.[1]
• However, the risk is significantly increased when semaglutide is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylureas).[1] Severe hypoglycemia can occur in such combinations.
• A reduction in the dose of concomitant insulin or sulfonylurea may be necessary to mitigate this risk.[30]
• Acute Kidney Injury (AKI):
• Postmarketing reports of AKI and worsening of chronic renal failure, sometimes requiring hemodialysis, have been associated with GLP-1 RAs, including semaglutide.[8]
• These events often occur in patients who experience significant nausea, vomiting, or diarrhea, leading to volume depletion (dehydration).[44] The causal link here is important: severe GI side effects can lead to dehydration, which in turn can precipitate or exacerbate AKI, especially in patients with pre-existing kidney disease or those taking concomitant nephrotoxic medications.
• Renal function should be monitored if severe GI adverse reactions occur, particularly during dose initiation or escalation, and in patients with pre-existing renal impairment.[49] Ensuring adequate hydration is crucial for patients experiencing such GI symptoms.
• Acute Gallbladder Disease:
• Events such as cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder) have been reported in clinical trials and postmarketing surveillance with semaglutide and other GLP-1 RAs.[8]
• Rapid weight loss is a known risk factor for cholelithiasis. Additionally, GLP-1 RAs may suppress cholecystokinin secretion and reduce gallbladder emptying, potentially contributing to gallstone formation.[44]
• If gallbladder disease is suspected, appropriate diagnostic studies and clinical follow-up are indicated.[49]
• Hypersensitivity Reactions:
• Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with semaglutide.[8]
• If a hypersensitivity reaction is suspected, semaglutide should be discontinued immediately, and appropriate medical treatment initiated.[49]
• Heart Rate Increase:
• Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) have been observed with semaglutide in clinical trials compared to placebo.[43] While generally modest, this effect should be considered in patients with pre-existing cardiac conditions where an increase in heart rate may be undesirable.
• Suicidal Behavior and Ideation:
• The Wegovy® label includes a warning to monitor for depression or suicidal thoughts, as these have been reported in clinical trials with other weight management products.[63] Patients should be advised to report any mood changes or suicidal ideation.
• Gastroparesis and Bowel Obstruction (Ileus):
• Given semaglutide's effect on delaying gastric emptying, there have been concerns and postmarketing reports of gastroparesis and ileus (bowel obstruction).[1] Rybelsus® and Ozempic® are not recommended in patients with severe gastroparesis.[49]

Many of semaglutide's adverse effects, such as GI disturbances and the potential for hypoglycemia when combined with insulin or sulfonylureas, are recognized class effects of GLP-1 RAs.[1] The warning regarding thyroid C-cell tumors is also a class-wide concern based on rodent studies, with its human relevance still under investigation.[88] The temporary worsening of diabetic retinopathy associated with rapid glycemic improvement is a known phenomenon not exclusive to semaglutide but is relevant given its potent glucose-lowering effects.[92] Understanding these distinctions is important for a balanced risk assessment.

6.3. Contraindications

Semaglutide is contraindicated in patients with:

• A personal or family history of Medullary Thyroid Carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[8]
• A prior serious hypersensitivity reaction to semaglutide or any of its excipients.[8]

6.4. Warnings and Precautions (not already covered as serious AEs)

• Never Share an Ozempic® Pen Between Patients: This practice carries a risk of transmitting blood-borne pathogens, even if the needle is changed.[53]
• Pulmonary Aspiration During General Anesthesia or Deep Sedation: Due to delayed gastric emptying, there is a potential risk of pulmonary aspiration of gastric contents if patients undergo procedures requiring general anesthesia or deep sedation. Patients should inform their healthcare providers about semaglutide use before any planned surgeries or procedures.[7]

6.5. Drug Interactions

• Oral Medications: Semaglutide delays gastric emptying, which can potentially alter the rate and extent of absorption of concomitantly administered oral medications.[21] While dedicated drug-drug interaction studies with Ozempic® showed no clinically relevant effects on the absorption of metformin, warfarin, digoxin, atorvastatin, ethinyl estradiol, or levonorgestrel [30], caution is advised, particularly with drugs that have a narrow therapeutic index or require rapid gastrointestinal absorption. Rybelsus® co-administration increased levothyroxine exposure by 33%, necessitating monitoring of thyroid function.[48]
• Insulin and Insulin Secretagogues (e.g., Sulfonylureas): Concomitant use significantly increases the risk of hypoglycemia. Dose reduction of insulin or sulfonylureas may be necessary when initiating semaglutide.[8]
• Other GLP-1 Receptor Agonists: Co-administration with other GLP-1 RAs is not recommended as this would be duplicative therapy.[38]

Table 3: Comprehensive Safety Profile of Semaglutide Formulations

Adverse Event Category	Specific Event/Contraindication/Warning	Details/Frequency (Ozempic®)	Details/Frequency (Rybelsus®)	Details/Frequency (Wegovy®)	Management/Monitoring Recommendations
Boxed Warning	Risk of Thyroid C-Cell Tumors (MTC)	Yes 53	Yes 49	Yes 63	Counsel on risk/symptoms. Contraindicated with personal/family history of MTC or MEN 2.
Common GI	Nausea	16-20% 53	11-20% (7mg/14mg) 49	~44% 77	Usually mild-moderate, transient, dose-escalation related. Manage symptomatically. Ensure hydration.
	Vomiting	5-9% 53	6-8% (7mg/14mg) 49	~25% 77	Usually mild-moderate, transient. Ensure hydration.
	Diarrhea	8-9% 53	9-10% (7mg/14mg) 49	~30% 77	Usually mild-moderate, transient. Ensure hydration.
	Constipation	3-5% 53	5-6% (7mg/14mg) 49	~24% 77	Dietary advice, hydration.
	Abdominal Pain	6-7% 53	10-11% (7mg/14mg) 49	~22% 77	Usually mild-moderate.
Serious Pancreatic	Acute Pancreatitis	Reported; discontinue if suspected 53	Reported; discontinue if suspected 49	Reported; discontinue if suspected 63	Monitor for persistent severe abdominal pain. Not studied in patients with prior pancreatitis.
Serious Ophthalmic	Diabetic Retinopathy Complications	3.0% vs 1.8% placebo (SUSTAIN-6) 53	4.2% vs 3.8% comparator (pooled) 49	Monitor in T2DM patients 63	Monitor patients with history of diabetic retinopathy, especially with rapid glucose improvement.
Serious Endocrine	Hypoglycemia (with insulin/SU)	Increased risk; dose reduction of insulin/SU may be needed 53	Increased risk; dose reduction of insulin/SU may be needed 49	Increased risk in T2DM patients; dose reduction of insulin/SU may be needed 63	Educate on symptoms. Monitor blood glucose. Adjust concomitant medication.
Serious Renal	Acute Kidney Injury	Postmarketing reports, often with dehydration from GI AEs 53	Postmarketing reports, often with dehydration from GI AEs 49	Postmarketing reports, often with dehydration from GI AEs 63	Monitor renal function if severe GI AEs or dehydration occur.
Serious Hepatobiliary	Acute Gallbladder Disease (Cholelithiasis, Cholecystitis)	Cholelithiasis 0.4-1.5% 53	Cholelithiasis 1% (7mg) 49	Reported 63	Evaluate if symptoms occur.
Serious Immune	Hypersensitivity Reactions (Anaphylaxis, Angioedema)	Reported; discontinue if suspected 53	Reported; discontinue if suspected 49	Reported; discontinue if suspected 63	Contraindicated with prior serious hypersensitivity.
Contraindications (General)	Personal/Family Hx of MTC or MEN 2	Yes 53	Yes 49	Yes 63	Absolute contraindication.
	Prior Serious Hypersensitivity to Semaglutide	Yes 53	Yes 49	Yes 63	Absolute contraindication.
Warnings (General)	Heart Rate Increase	Mean 2-3 bpm 53	Mean 1-3 bpm 49	Mean 1-4 bpm 63	Monitor heart rate as appropriate.
	Suicidal Behavior/Ideation	Not specified in Ozempic PI	Not specified in Rybelsus PI	Monitor for depression/suicidal thoughts 63	Counsel patients to report.
	Ileus/Gastroparesis	Postmarketing reports of ileus. Not recommended in severe gastroparesis 53	Postmarketing reports of ileus. Not recommended in severe gastroparesis 49	Postmarketing reports of ileus. Not recommended in severe gastroparesis 63	Caution in patients with history of gastroparesis.

7. Dosing and Administration

Proper dosing and administration are crucial for optimizing the efficacy and minimizing adverse effects of semaglutide. The specific regimens vary by formulation and indication, with a common principle of gradual dose escalation to improve gastrointestinal tolerability.

7.1. Ozempic® (Subcutaneous Injection)

• Type 2 Diabetes Mellitus (T2DM):
• The recommended starting dosage is 0.25 mg once weekly for 4 weeks. This initial dose is intended for treatment initiation and is not effective for glycemic control.[18]
• After 4 weeks on the 0.25 mg dose, the dosage should be increased to 0.5 mg once weekly.[18]
• If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dose, the dosage may be increased to 1 mg once weekly.[18]
• If further glycemic control is required after at least 4 weeks on the 1 mg dose, the dosage may be increased to a maximum of 2 mg once weekly.[18]
• Cardiovascular Risk Reduction in T2DM: The dosing regimen follows that for T2DM. The SUSTAIN-6 trial primarily used 0.5 mg and 1 mg doses.[18]
• Chronic Kidney Disease in T2DM: The recommended maintenance dosage for this indication is 1 mg once weekly, achieved after the standard titration from 0.25 mg to 0.5 mg, and then to 1 mg.[9]
• Administration: Ozempic® is administered once weekly on the same day each week, at any time of day, with or without meals. It should be injected subcutaneously into the abdomen, thigh, or upper arm. Injection sites should be rotated within the same body region to reduce the risk of lipodystrophy.[18] The day of weekly administration can be changed if necessary, provided the time between two doses is at least 2 days (>48 hours).[18]

7.2. Rybelsus® (Oral Tablets)

• Type 2 Diabetes Mellitus (T2DM):
• Formulation R1 (3 mg, 7 mg, 14 mg tablets):
• Start with 3 mg once daily for 30 days. This 3 mg dosage is for treatment initiation and is not effective for glycemic control.[19]
• After 30 days on the 3 mg dosage, increase the dosage to 7 mg once daily.[19]
• If additional glycemic control is needed after at least 30 days on the 7 mg dosage, the dosage may be increased to 14 mg once daily.[19] Taking two 7 mg tablets to achieve a 14 mg dose is not recommended.[42]
• Formulation R2 (1.5 mg, 4 mg, 9 mg tablets):
• Start with 1.5 mg once daily for 30 days (non-therapeutic initiation dose).[21]
• After 30 days, increase to 4 mg once daily.[21]
• If further glycemic control is needed after at least 30 days on the 4 mg dose, the dosage may be increased to 9 mg once daily.[21]
• The two formulations (R1 and R2) are not substitutable on a milligram-per-milligram basis and should not be used simultaneously.[21]
• Administration: Rybelsus® tablets must be taken at least 30 minutes before the first food, beverage, or other oral medications of the day, with no more than 4 ounces (120 mL) of plain water only. Waiting less than 30 minutes, or taking with food, beverages (other than plain water), or other oral medications will lessen the effect of Rybelsus® by decreasing its absorption. Waiting more than 30 minutes to eat may increase the absorption. Tablets should be swallowed whole and not split, crushed, or chewed.[19]

7.3. Wegovy® (Subcutaneous Injection)

• Chronic Weight Management and Cardiovascular Risk Reduction in Adults:
• Initiate Wegovy® at a dosage of 0.25 mg once weekly for the first 4 weeks.[4]
• The dosage should be escalated every 4 weeks according to the following schedule: 0.5 mg once weekly for weeks 5-8; 1.0 mg once weekly for weeks 9-12; 1.7 mg once weekly for weeks 13-16.[4]
• The recommended maintenance dosage is 2.4 mg once weekly, starting from week 17 onwards. A maintenance dosage of 1.7 mg once weekly is also an option if the 2.4 mg dose is not tolerated.[4]
• Chronic Weight Management in Pediatric Patients (Aged 12 Years and Older): The dosage escalation schedule is the same as for adults, with a target maintenance dose of 2.4 mg once weekly.[35]
• Administration: Wegovy® is administered once weekly on the same day each week, at any time of day, with or without meals. It should be injected subcutaneously into the abdomen, thigh, or upper arm. Injection sites should be rotated.[35] The day of weekly administration can be changed if necessary, as long as the time between two doses is at least 2 days (>48 hours).[35]

The consistent requirement for gradual dose escalation across all semaglutide products is a direct strategy to mitigate the common gastrointestinal side effects associated with GLP-1 RAs.[18] By allowing the patient's body to slowly adapt to the medication, the incidence and severity of nausea, vomiting, and diarrhea can often be reduced, thereby improving overall tolerability and patient adherence to long-term treatment.

7.4. Missed Doses

• Ozempic® / Wegovy® (Subcutaneous): If a dose is missed, it should be administered as soon as possible within 5 days after the missed dose. If more than 5 days have passed, the missed dose should be skipped, and the next dose should be administered on the regularly scheduled day. When changing the weekly administration day, it is important to ensure that there are at least 2 days (>48 hours) between doses.[18] If Wegovy® doses are missed for more than 2 consecutive weeks, the next dose should be taken on the regularly scheduled day, or the patient should consult their healthcare provider about how to restart treatment, which may involve re-initiating the dose escalation schedule.[63]
• Rybelsus® (Oral): If a dose is missed, the missed dose should be skipped, and the next dose should be taken the following day as regularly scheduled. Patients should not take an extra dose to make up for the missed dose.[19]

8. Regulatory Landscape

Semaglutide, under its various brand names, has received approvals from major regulatory health authorities worldwide for its distinct indications. The regulatory journey reflects its evolving therapeutic profile, from a T2DM treatment to a comprehensive cardiometabolic and renal protective agent.

8.1. Regulatory Approvals and Indications by Authority

Table 4: Semaglutide Regulatory Approval Summary (Selected Authorities)

Brand Name	Formulation	Regulatory Authority	Initial Approval Date	Key Approved Indications	Relevant Snippets
Ozempic®	Subcutaneous Injection	FDA (USA)	December 2017	- T2DM (glycemic control) <br> - CV risk reduction in T2DM with CVD <br> - CKD risk reduction in T2DM with CKD (Jan 2025)	User Query, 1
		EMA (EU)	February 8, 2018	- T2DM (glycemic control) <br> - CV risk reduction data included in label (Dec 2024 update for kidney benefits)	1
		Health Canada	January 4, 2018	- T2DM (glycemic control) <br> - CV risk reduction in T2DM with CVD and/or CKD (SNDS for this was filed, status of specific approval for this wording needs confirmation from monograph)	71
		PMDA (Japan)	March 23, 2018	- T2DM (glycemic control)	9
		TGA (Australia)	Approved (date not specified in snippets, but marketed)	- T2DM (glycemic control)	96
Rybelsus®	Oral Tablets	FDA (USA)	September 20, 2019	- T2DM (glycemic control)	User Query, 1
		EMA (EU)	April 3, 2020	- T2DM (glycemic control)	1
		Health Canada	March 30, 2020	- T2DM (glycemic control)	91
		PMDA (Japan)	June 29, 2020	- T2DM (glycemic control)	133
		TGA (Australia)	February 7, 2022	- T2DM (glycemic control)	140
Wegovy®	Subcutaneous Injection	FDA (USA)	June 2021 (weight management); March 8, 2024 (CV risk reduction)	- Chronic weight management (adults & adolescents ≥12 yrs) <br> - CV risk reduction in adults with CVD and obesity/overweight	User Query, 1
		EMA (EU)	January 6, 2022	- Chronic weight management (adults & adolescents ≥12 yrs) <br> - CV risk reduction data included in label (2024/2025 update)	1
		Health Canada	November 23, 2021 (weight management); November 27, 2024 (non-fatal MI risk reduction)	- Chronic weight management (adults & adolescents ≥12 yrs) <br> - Reduction of non-fatal MI risk in adults with CVD and BMI ≥27 kg/m²	1
		PMDA (Japan)	March 27, 2023	- Obesity (with comorbidities if BMI 27-35; or BMI ≥35)	133
		TGA (Australia)	Approved (date for weight management not specified, but available Aug 2024); Dec 2024 (CV risk reduction indication added)	- Chronic weight management <br> - CV risk reduction in adults with CVD and BMI ≥27 kg/m²	119

Note: Approval dates and specific indication wordings can vary slightly between sources and may be subject to updates. CV = Cardiovascular; CKD = Chronic Kidney Disease; MACE = Major Adverse Cardiovascular Event; MI = Myocardial Infarction; T2DM = Type 2 Diabetes Mellitus.

The regulatory trajectory of semaglutide clearly reflects its expanding evidence base. Initial approvals focused on glycemic control in T2DM. As substantial weight loss benefits became evident in these trials, and were confirmed in dedicated obesity studies (STEP program), approvals for chronic weight management followed. Subsequently, positive outcomes from large cardiovascular (SUSTAIN-6, PIONEER-6, SELECT) and renal (FLOW) trials led to landmark indication expansions for reducing cardiovascular risk and protecting kidney function in specific high-risk populations. This progression demonstrates a responsive regulatory environment that adapts to new, robust clinical evidence, ultimately broadening patient access to multifaceted therapies.

8.2. FDA Warning on Compounded Semaglutide

On May 31, 2023, the U.S. Food and Drug Administration (FDA) issued a warning regarding the use of compounded semaglutide after receiving adverse event reports.[26] Key concerns highlighted by the FDA include:

• Use of Salt Forms: The FDA noted that some compounded semaglutide products may use salt forms of semaglutide, such as semaglutide sodium and semaglutide acetate.[26] The agency stated that these salt forms are different active ingredients than the base form of semaglutide found in the FDA-approved drug products. The FDA does not have information on whether these salt forms have the same chemical and pharmacological properties as the approved drug and is not aware of any lawful basis for their use in compounding.[106]
• Lack of FDA Approval and Oversight: Compounded drugs are not FDA-approved, meaning they do not undergo the agency's rigorous review for safety, effectiveness, or quality before marketing.[106]
• Dosing Errors and Adverse Events: The FDA has received reports of adverse events, some requiring hospitalization, potentially related to dosing errors with compounded injectable semaglutide products. These errors have resulted from patients self-administering incorrect doses or healthcare professionals miscalculating doses. Adverse events reported include serious gastrointestinal issues.[106]
• Counterfeit Products: The FDA has also identified counterfeit versions of Ozempic® circulating in the U.S. drug supply chain, which may contain incorrect ingredients, incorrect dosages, or harmful substances.[107]

The FDA recommends that patients obtain prescriptions from their doctors and fill them at state-licensed pharmacies to ensure they are receiving authentic, FDA-approved medication.[106]

9. Comparative Efficacy and Market Context

9.1. Comparison with Other GLP-1 Receptor Agonists

Semaglutide has demonstrated strong efficacy in glycemic control and weight reduction, often showing superiority or favorable outcomes when compared to other GLP-1 RAs in head-to-head trials or meta-analyses.

• Glycemic Control (HbA1c Reduction):
• vs. Dulaglutide: In the SUSTAIN 7 trial, subcutaneous semaglutide (0.5 mg and 1.0 mg) showed statistically superior HbA1c reductions compared to dulaglutide (0.75 mg and 1.5 mg).[55]
• vs. Exenatide ER: In SUSTAIN 3, subcutaneous semaglutide 1.0 mg resulted in a greater HbA1c reduction (-1.5%) compared to exenatide ER 2.0 mg (-0.9%).[55]
• vs. Liraglutide: In PIONEER 4, oral semaglutide 14 mg was non-inferior to subcutaneous liraglutide 1.8 mg for HbA1c reduction.[49] SUSTAIN 10 (Japan) showed oral semaglutide led to greater HbA1c reduction than liraglutide.[55]
• A meta-analysis suggested semaglutide was statistically superior to other GLP-1 RAs in terms of glycemic control.[109]
• Weight Loss:
• Semaglutide generally demonstrates superior weight loss compared to liraglutide and dulaglutide.[109] A meta-analysis showed semaglutide led to a greater mean weight loss compared to liraglutide (-6.08 kg difference) and dulaglutide (-2.85 kg difference).[111]
• In SUSTAIN 3, semaglutide 1.0 mg led to a mean weight loss of 5.6 kg versus 1.9 kg with exenatide ER.[110]
• In PIONEER 4, oral semaglutide 14 mg resulted in greater weight loss (-4.4 kg) than liraglutide 1.8 mg (-3.1 kg).[49]
• Cardiovascular Outcomes:
• Liraglutide (LEADER trial), subcutaneous semaglutide (SUSTAIN-6), and dulaglutide (REWIND trial) have all demonstrated a reduction in MACE in patients with T2DM and high CV risk.[64]
• Oral semaglutide (PIONEER 6) showed non-inferiority for MACE and a significant reduction in CV death and all-cause mortality.[15]
• Wegovy® (semaglutide 2.4 mg) in the SELECT trial demonstrated a 20% MACE reduction in patients with overweight/obesity and established CVD without diabetes, a unique finding for this patient population among GLP-1 RAs.[5]
• Renal Outcomes:
• Semaglutide, dulaglutide, and liraglutide have shown benefits in composite renal outcomes, primarily driven by reductions in new or persistent macroalbuminuria.[109] The FLOW trial specifically established Ozempic's efficacy in reducing major kidney disease events in T2DM patients with CKD.[8]

9.2. Comparison with Tirzepatide (Dual GIP/GLP-1 Receptor Agonist)

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, has emerged as a significant comparator and competitor.

• Weight Loss: Systematic reviews and indirect comparisons of Phase 3 trial data (e.g., STEP for semaglutide, SURMOUNT for tirzepatide) suggest that tirzepatide (particularly at 10 mg and 15 mg doses) may lead to greater mean weight loss than semaglutide 2.4 mg in individuals with obesity, with or without T2DM.[111] One analysis reported an additional 4-5.4% weight loss with tirzepatide.[112] The SURMOUNT-5 head-to-head trial indicated tirzepatide achieved 20.2% weight loss compared to 13.7% with Wegovy® at 72 weeks.[115]
• Glycemic Control: Tirzepatide has also shown superior HbA1c reductions compared to semaglutide in some comparative settings.[112]
• Safety: Some analyses suggest tirzepatide may have fewer gastrointestinal side effects compared to semaglutide 2.4 mg, though both are generally characterized by mild-to-moderate GI AEs.[111] It is important to note that direct head-to-head trials are the gold standard for definitive comparisons, and while SURMOUNT-5 provides such data, more comparative studies are anticipated to fully elucidate relative profiles.

9.3. GLP-1 Receptor Agonist Market Landscape

The GLP-1 RA market is experiencing explosive growth, driven by the dual epidemics of T2DM and obesity, and the expanding evidence for cardiovascular and renal benefits.

• Market Size and Growth: The global GLP-1 RA market was estimated at USD 53.5 billion in 2024 and is projected to reach USD 268.37 billion by 2034, with a CAGR of 17.5%.[116] Another report estimates growth from USD 49.3 billion to USD 157.5 billion by 2035 (CAGR 11.1%).[117]
• Dominant Players: Novo Nordisk (with semaglutide and liraglutide) and Eli Lilly (with dulaglutide and tirzepatide) are the leading companies in this space.[116]
• Semaglutide's Position: Semaglutide (Ozempic®, Rybelsus®, Wegovy®) currently holds the largest market share among active GLP-1 compounds.[117] Ozempic® sales alone exceeded $13.9 billion in 2023.[116]
• Key Trends:
• Route of Administration: While parenteral (subcutaneous) formulations currently dominate, oral formulations (like Rybelsus®) are expected to see higher growth rates.[117]
• Agonist Type: Single agonists are prevalent, but dual-agonists (like tirzepatide) and emerging tri-agonists are expected to gain traction.[117]
• Indications: T2DM is the largest segment, but obesity and non-alcoholic steatohepatitis (NASH) are rapidly growing areas of application.[117]
• Geographic Distribution: North America is the largest market, with Asia-Pacific expected to be the fastest-growing region.[116]
• Emerging Competitors: Besides tirzepatide, other GLP-1 RAs and multi-agonists like survodutide, orforglipron, retatrutide, and ecnoglutide are in late-stage development and poised to enter the market, increasing competition.[117]
• Challenges: The high cost of GLP-1 RAs remains a significant barrier to access for many patients.[116] Supply shortages due to overwhelming demand have also been an issue.[118]

The strong clinical profile of semaglutide, particularly its robust efficacy in weight loss and its proven cardiovascular and renal benefits across diverse patient populations, positions it as a cornerstone therapy. However, the market is dynamic, with novel agents, particularly multi-receptor agonists like tirzepatide, demonstrating potentially superior efficacy in some domains. The future landscape will likely involve a broader array of GLP-1 based therapies with varying mechanisms and delivery systems, aiming to provide more personalized treatment options.

10. Conclusion

Semaglutide has emerged as a transformative therapeutic agent, fundamentally altering the management landscape for type 2 diabetes mellitus, obesity, and associated cardiometabolic-renal complications. Its development, characterized by strategic molecular modifications to mimic and enhance the actions of native GLP-1, has resulted in a pharmacological profile that supports convenient dosing and delivers profound clinical benefits.

The robust efficacy of semaglutide in improving glycemic control (Ozempic®, Rybelsus®) and inducing substantial, sustained weight loss (Wegovy®, Ozempic®, Rybelsus®) is well-established through extensive Phase 3 clinical trial programs (SUSTAIN, PIONEER, STEP). Beyond these primary metabolic effects, semaglutide has demonstrated significant cardiovascular risk reduction in patients with T2DM and established CVD (Ozempic® - SUSTAIN-6), in T2DM patients at high CV risk (Rybelsus® - PIONEER 6 showing CV safety), and remarkably, in individuals with overweight or obesity and established CVD without diabetes (Wegovy® - SELECT trial). Furthermore, the FLOW trial has solidified its role in providing significant renoprotection for adults with T2DM and chronic kidney disease (Ozempic®). This broad spectrum of efficacy underscores the interconnected nature of metabolic, cardiovascular, and renal health, and highlights GLP-1 receptor agonism as a key therapeutic pathway.

The pharmacokinetic profile of semaglutide, marked by a long elimination half-life of approximately one week due to DPP-4 resistance and extensive albumin binding, allows for once-weekly subcutaneous administration (Ozempic®, Wegovy®). The innovative oral formulation (Rybelsus®), utilizing SNAC technology for gastric absorption, offers a non-injectable alternative, though its bioavailability is lower and dependent on strict administration protocols.

While generally well-tolerated, particularly with gradual dose escalation, semaglutide is associated with common gastrointestinal adverse effects. Important safety considerations include the boxed warning for the risk of thyroid C-cell tumors (based on rodent data), and risks of acute pancreatitis, diabetic retinopathy complications (with rapid glucose lowering), hypoglycemia (when combined with insulin or sulfonylureas), acute kidney injury (often linked to dehydration from GI effects), and gallbladder disease. Careful patient selection, counseling, and monitoring are essential.

Regulatory agencies worldwide, including the FDA, EMA, Health Canada, PMDA, and TGA, have granted approvals for semaglutide's various formulations and expanding indications, reflecting the strength of its clinical data. However, challenges such as the high cost of therapy and intermittent supply shortages due to high demand persist. The FDA has also issued warnings regarding unapproved compounded versions of semaglutide, particularly those using unverified salt forms.

In the competitive landscape of GLP-1 based therapies, semaglutide currently holds a leading market position. However, newer agents, including dual GIP/GLP-1 receptor agonists like tirzepatide, are demonstrating comparable or even superior efficacy in some parameters, heralding an era of ongoing innovation and competition in this therapeutic space.

In summary, semaglutide represents a cornerstone in the management of T2DM and obesity, offering not only potent metabolic control but also significant, evidence-based cardiovascular and renal protection. Its development and expanding indications exemplify the progress in understanding and treating complex chronic diseases through targeted incretin-based therapies. Future research will likely continue to explore its full therapeutic potential and refine its use in diverse patient populations.

Works cited

1. Semaglutide - Wikipedia, accessed May 23, 2025, https://en.wikipedia.org/wiki/Semaglutide
2. Semaglutide, also known as Ozempic, for weight loss - what you ..., accessed May 23, 2025, https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know
3. www.guidetopharmacology.org, accessed May 23, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9724#:~:text=Comment%3A%20Semaglutide%20is%20a%20glucagon,is%20acylated%20with%20stearic%20diacid.
4. Prescription Weight Loss Medication | Wegovy® (semaglutide ..., accessed May 23, 2025, https://www.wegovy.com/
5. Early cardiovascular benefits of semaglutide seen within months in SELECT trial, accessed May 23, 2025, https://www.news-medical.net/news/20250512/Early-cardiovascular-benefits-of-semaglutide-seen-within-months-in-SELECT-trial.aspx
6. Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity | JACC, accessed May 23, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2024.11.008
7. Ozempic: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed May 23, 2025, https://www.drugs.com/ozempic.html
8. Can Ozempic Reduce Risks from Chronic Kidney Disease in Diabetes Patients?, accessed May 23, 2025, https://www.metropolitankidney.com/can-ozempic-reduce-risks-from-chronic-kidney-disease-in-diabetes-patients
9. FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease - Novo Nordisk, accessed May 23, 2025, https://www.novonordisk-us.com/media/news-archive/news-details.html?id=915253
10. SUSTAIN 1 to 5 trial designs | Download Table - ResearchGate, accessed May 23, 2025, https://www.researchgate.net/figure/SUSTAIN-1-to-5-trial-designs_tbl1_325566550
11. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials - PMC - PubMed Central, accessed May 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6099440/
12. Semaglutide 7.2 mg Displays 20.7% Weight Loss in Phase 3b STEP UP Trial - HCPLive, accessed May 23, 2025, https://www.hcplive.com/view/semaglutide-7-2-mg-displays-20-7-weight-loss-in-phase-3b-step-up-trial
13. STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo - Applied Clinical Trials, accessed May 23, 2025, https://www.appliedclinicaltrialsonline.com/view/step-up-trial-semaglutide-superior-weight-loss
14. Key CVOTs with Semaglutide: SUSTAIN 6 and PIONEER 6, accessed May 23, 2025, https://www.acc.org/Latest-in-Cardiology/Articles/2020/01/02/15/05/Key-CVOTs-with-Semaglutide
15. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes - IRIS UniPA, accessed May 23, 2025, https://iris.unipa.it/bitstream/10447/370703/2/BUSCEMI%20PIONEER%206%20nejmoa1901118.pdf
16. FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease - PR Newswire, accessed May 23, 2025, https://www.prnewswire.com/news-releases/fda-approves-ozempic-semaglutide-as-the-only-glp-1-ra-to-reduce-the-risk-of-worsening-kidney-disease-and-cardiovascular-death-in-adults-with-type-2-diabetes-and-chronic-kidney-disease-302362466.html
17. Request or activate your Ozempic ® Savings Offer - NovoCare, accessed May 23, 2025, https://www.novocare.com/diabetes/products/ozempic/savings-offer.html
18. Dosing & Prescribing | Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, accessed May 23, 2025, https://www.novomedlink.com/diabetes/products/treatments/ozempic/dosing-administration/dosing-and-prescribing.html
19. RYBELSUS® (semaglutide) tablets 7 mg or 14 mg Savings Offer Result | NovoCare®, accessed May 23, 2025, https://www.novocare.com/diabetes/products/rybelsus/savings-offer/result.html
20. RYBELSUS® (semaglutide) tablets 7 mg or 14 mg Savings Offer | NovoCare®, accessed May 23, 2025, https://www.novocare.com/diabetes/products/rybelsus/savings-offer.html
21. Rybelsus: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed May 23, 2025, https://www.drugs.com/rybelsus.html
22. Wegovy® (semaglutide) injection 2.4 mg Savings Offer & Support Program | NovoCare®, accessed May 23, 2025, https://www.novocare.com/obesity/products/wegovy/savings-offer.html
23. Managing Weight with Wegovy® | Wegovy® (semaglutide) Injection 2.4 mg, accessed May 23, 2025, https://www.wegovy.com/about-wegovy/managing-weight-with-wegovy.html
24. Semaglutide Completed Phase 2 Trials for Type 2 Diabetes Mellitus / Diabetes Mellitus Treatment | DrugBank Online, accessed May 23, 2025, https://go.drugbank.com/drugs/DB13928/clinical_trials?conditions=DBCOND0027886%2CDBCOND0029752&phase=2&purpose=treatment&status=completed
25. Clinical Pharmacokinetics of Semaglutide: A Systematic Review - ResearchGate, accessed May 23, 2025, https://www.researchgate.net/publication/381716428_Clinical_Pharmacokinetics_of_Semaglutide_A_Systematic_Review
26. Semaglutide | C187H291N45O59 | CID 56843331 - PubChem, accessed May 23, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/56843331
27. The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity | PNAS, accessed May 23, 2025, https://www.pnas.org/doi/10.1073/pnas.2415550121
28. Semaglutide: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed May 23, 2025, https://go.drugbank.com/drugs/DB13928
29. semaglutide | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed May 23, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9724
30. Ozempic, INN-semaglutide - European Medicines Agency, accessed May 23, 2025, https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf
31. EP1863839B1 - Acylated glp-1 compounds - Google Patents, accessed May 23, 2025, https://patents.google.com/patent/EP1863839B1/en
32. Comparative Bioavailability Study of Rybelsus (Semaglutide) 3 mg Tablets - Walsh Medical Media, accessed May 23, 2025, https://www.walshmedicalmedia.com/open-access/comparative-bioavailability-study-of-rybelsus-semaglutide-3-mg-tablets-of-novo-nordisk-iversusi-ozempic-semaglutide-2-mg.pdf
33. Mechanism of absorption of oral semaglutide. SNAC indicates sodium... - ResearchGate, accessed May 23, 2025, https://www.researchgate.net/figure/Mechanism-of-absorption-of-oral-semaglutide-SNAC-indicates-sodium_fig1_347894668
34. OZEMPIC (semaglutide) injection, for subcutaneous use - accessdata.fda.gov, accessed May 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
35. Wegovy® (semaglutide) solution for injection - Medsinfo, accessed May 23, 2025, https://rss.medsinfo.com.au/no/pi.cfm?product=nopwegov
36. Wegovy Dosage: Form, Strengths, How to Use It, and More - Healthline, accessed May 23, 2025, https://www.healthline.com/health/drugs/wegovy-dosage
37. Wegovy® Dosing Schedule | Wegovy® (semaglutide) Injection 2.4 mg, accessed May 23, 2025, https://www.wegovy.com/taking-wegovy/dosing-schedule.html
38. Ozempic, Rybelsus, Wegovy (semaglutide) dosing, indications, interactions, adverse effects, and more - Medscape, accessed May 23, 2025, https://reference.medscape.com/drug/ozempic-rybelsus-wegovy-semaglutide-1000174
39. Rybelsus CI - Novo Nordisk Canada, accessed May 23, 2025, https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/Rybelsus-CI-EN-monograph.pdf
40. Rybelsus Dosage Guide: Recommendations and Adjustments - GoodRx, accessed May 23, 2025, https://www.goodrx.com/rybelsus/dosage
41. What is SNAC in oral semaglutide? - Biopharma PEG, accessed May 23, 2025, https://www.biochempeg.com/article/370.html
42. RYBELSUS (semaglutide) tablets, for oral use. - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed May 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s018lbl.pdf
43. (PDF) Semaglutide (Ozempic ® ): a comprehensive review of its pharmacology, efficacy, and safety profile in type 2 diabetes mellitus and weight management - ResearchGate, accessed May 23, 2025, https://www.researchgate.net/publication/388790459_Semaglutide_Ozempic_R_a_comprehensive_review_of_its_pharmacology_efficacy_and_safety_profile_in_type_2_diabetes_mellitus_and_weight_management
44. Semaglutide - StatPearls - NCBI Bookshelf, accessed May 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK603723/
45. How does semaglutide work? - Mayo Clinic Diet, accessed May 23, 2025, https://diet.mayoclinic.org/us/blog/2024/how-does-semaglutide-work/
46. How Does Semaglutide Affect Your Digestive System? - Raymond Lau Family Medicine PC, accessed May 23, 2025, https://raymondlaufmpc.com/semaglutide-affect-your-digestive-system/
47. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | Request PDF - ResearchGate, accessed May 23, 2025, https://www.researchgate.net/publication/380144417_Long-Term_Efficacy_and_Safety_of_Once-Weekly_Semaglutide_for_Weight_Loss_in_Patients_Without_Diabetes_A_Systematic_Review_and_Meta-Analysis_of_Randomized_Controlled_Trials
48. Semaglutide Monograph for Professionals - Drugs.com, accessed May 23, 2025, https://www.drugs.com/monograph/semaglutide.html
49. www.novo\-pi.com, accessed May 23, 2025, https://www.novo-pi.com/rybelsus.pdf
50. RYBELSUS® Mechanism of Action | RYBELSUS® (semaglutide) tablets 7 mg or 14 mg - novoMEDLINK, accessed May 23, 2025, https://www.novomedlink.com/diabetes/products/treatments/rybelsus/about/mechanism-of-action.html
51. Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme - PMC, accessed May 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9321749/
52. Renal Impairment & Special Populations | RYBELSUS® (semaglutide) tablets 7 mg or 14 mg - novoMEDLINK, accessed May 23, 2025, https://www.novomedlink.com/diabetes/products/treatments/rybelsus/patient-population/specific-populations.html
53. www.novo\-pi.com, accessed May 23, 2025, https://www.novo-pi.com/ozempic.pdf
54. Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials - Oxford Academic, accessed May 23, 2025, https://academic.oup.com/jcem/article/105/2/543/5643670
55. A quick guide to the SUSTAIN trials - medwirenews.com, accessed May 23, 2025, https://www.medwirenews.com/showcase/a-quick-guide-to-the-sustain-trials/
56. 787-P: Glucose and Weight Outcomes Associated with Oral Semaglutide in the Real-World—Initial Results from the Association of British Clinical Diabetologists' (ABCD) Audit | Diabetes, accessed May 23, 2025, https://diabetesjournals.org/diabetes/article/72/Supplement_1/787-P/149494
57. Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses - PMC, accessed May 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7994454/
58. Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study | springermedizin.de, accessed May 23, 2025, https://www.springermedizin.de/effectiveness-of-oral-semaglutide-on-glucose-control-and-body-we/26747654
59. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes - PubMed, accessed May 23, 2025, https://pubmed.ncbi.nlm.nih.gov/31186300/
60. A1C and Weight Results | RYBELSUS® (semaglutide) tablets 7 mg or 14 mg - novoMEDLINK, accessed May 23, 2025, https://www.novomedlink.com/diabetes/products/treatments/rybelsus/efficacy-safety/A1C-and-weight-data.html
61. Semaglutide for the treatment of overweight and obesity: A review - PMC - PubMed Central, accessed May 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10092086/
62. Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial, accessed May 23, 2025, https://www.biospace.com/drug-development/novo-nordisk-links-high-dose-wegovy-to-increased-weight-loss-in-phase-iii-trial
63. www.novo\-pi.com, accessed May 23, 2025, https://www.novo-pi.com/wegovy.pdf
64. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6 - Frontiers, accessed May 23, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.645566/full
65. Cardiovascular Outcomes, Safety, and Tolerability With Oral Semaglutide: Insights for Managed Care, accessed May 23, 2025, https://www.ajmc.com/view/cardiovascular-outcomes-safety-and-tolerability-with-oral-semaglutide-insights-for-managed-care
66. Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT, accessed May 23, 2025, https://diabetesjournals.org/care/article/47/8/1360/156810/Semaglutide-and-Cardiovascular-Outcomes-by
67. SELECT Trial - Cardionerds, accessed May 23, 2025, https://www.cardionerds.com/cardsjc-semaglutide-and-cardiovascular-outcomes-in-obesity-without-diabetes-select-trial/
68. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, accessed May 23, 2025, https://mediacenteratypon.nejmgroup-production.org/NEJMoa2307563.pdf
69. accessed January 1, 1970, https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
70. Weight loss drug Wegovy gains FDA approval to reduce heart disease risk, accessed May 23, 2025, https://www.medicalnewstoday.com/articles/fda-approves-wegovy-to-reduce-heart-disease-risk
71. Ozempic Now Approved for Kidney Disease Treatment - JoinAStudy.ca, accessed May 23, 2025, https://joinastudy.ca/ozempic-now-approved-for-kidney-disease-treatment/
72. Dosing & Side Effects | RYBELSUS® (semaglutide) tablets, accessed May 23, 2025, https://www.rybelsus.com/taking-rybelsus/what-to-expect-with-rybelsus.html
73. The Ozempic Effect: Everything You Need to Know About Medical Weight Loss, accessed May 23, 2025, https://columbiasurgery.org/news/ozempic-effect-everything-you-need-know-about-medical-weight-loss
74. Important Safety Information | Ozempic® (semaglutide) injection 0.5 mg or 1 mg, accessed May 23, 2025, https://www.ozempic.com/important-safety-information.html
75. Possible Side Effects of Ozempic ® (semaglutide) Injection, accessed May 23, 2025, https://www.ozempic.com/how-to-take/side-effects.html
76. Rybelsus (semaglutide): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed May 23, 2025, https://www.webmd.com/drugs/2/drug-178019/rybelsus-oral/details
77. Wegovy® Safety Profile - novoMEDLINK, accessed May 23, 2025, https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/safety-profile.html
78. Wegovy (semaglutide): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed May 23, 2025, https://www.webmd.com/drugs/2/drug-181658/wegovy-subcutaneous/details
79. Ozempic and Pancreatitis: Can Semaglutide Cause Pancreatitis? - Mission: Cure, accessed May 23, 2025, https://mission-cure.org/ozempic-and-pancreatitis/
80. Can Semaglutide Cause Pancreatitis? - Gupta Plastic Surgery, accessed May 23, 2025, https://www.guptaplasticsurgery.com/blog/can-semaglutide-cause-pancreatitis.html
81. Acute Kidney Injury Associated With Semaglutide - PMC, accessed May 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8039426/
82. Understanding Semaglutide Drug Interactions: A Comprehensive Guide, accessed May 23, 2025, https://www.drvaesthetics.com/understanding-semaglutide-drug-interactions-a-comprehensive-guide/
83. FDA Approves New Use for Ozempic to Reduce the Risks of Kidney Disease - Xtalks, accessed May 23, 2025, https://xtalks.com/fda-approves-new-use-for-ozempic-to-reduce-the-risks-of-kidney-disease-4070/
84. New Indications Added to Ozempic Approval for CKD, CVD - U.S. Pharmacist, accessed May 23, 2025, https://www.uspharmacist.com/article/new-indications-added-to-ozempic-approval-for-ckd-cvd
85. Ozempic picks up FDA indication to treat chronic kidney disease - Renal Interventions, accessed May 23, 2025, https://renalinterventions.net/ozempic-picks-up-fda-indication-to-treat-chronic-kidney-disease/
86. Ozempic® (semaglutide) injection for Type 2 Diabetes, accessed May 23, 2025, https://www.ozempic.com/
87. FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular deat, accessed May 23, 2025, https://www.ozempic.com/content/dam/diabetes-patient/ozempic/pdfs/Ozempic_CKD_sNDA_Press_Release_January_28_2025.pdf
88. Semaglutide for Weight Loss in Patients with a Family History of Thyroid or Uterine Cancer: A Systemic Review | medRxiv, accessed May 23, 2025, https://www.medrxiv.org/content/10.1101/2025.02.27.25323032v2
89. Can Semaglutide (Ozempic) Cause Cancer? - GoodRx, accessed May 23, 2025, https://www.goodrx.com/ozempic/does-semaglutide-cause-cancer
90. FDA approves first oral GLP-1 treatment for type 2 diabetes, accessed May 23, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes
91. Rybelsus® (semaglutide tablets) Product Monograph - Novo Nordisk Canada, accessed May 23, 2025, https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/Rybelsus-PM-EN-monograph.pdf
92. Semaglutide and Associated Ophthalmic Risks - EyeWiki, accessed May 23, 2025, https://eyewiki.org/Semaglutide_and_Associated_Ophthalmic_Risks
93. Semaglutide linked to higher risk of vision problems, FDA data analysis shows, accessed May 23, 2025, https://www.news-medical.net/news/20250408/Semaglutide-linked-to-higher-risk-of-vision-problems-FDA-data-analysis-shows.aspx
94. Semaglutide | Interactions - BNF - NICE, accessed May 23, 2025, https://bnf.nice.org.uk/interactions/semaglutide/
95. Ozempic 0.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc) | 9750, accessed May 23, 2025, https://www.medicines.org.uk/emc/product/9750/smpc
96. Ozempic® - Novo Nordisk Australia, accessed May 23, 2025, https://www.novonordisk.com.au/content/dam/nncorp/au/en/pdfs/Ozempic-1mg-cmi-v3.0.pdf
97. Attachment Product information for Wegovy - Therapeutic Goods Administration (TGA), accessed May 23, 2025, https://www.tga.gov.au/sites/default/files/2024-09/auspar-wegovy-01-240904-pi.pdf
98. Wegovy (semaglutide) injection - accessdata.fda.gov, accessed May 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256Orig1s006lbl.pdf
99. Rybelsus 3 mg - Patient Information Leaflet (PIL) - (emc) | 11507, accessed May 23, 2025, https://www.medicines.org.uk/emc/product/11507/pil
100. Rybelsus dosage: Form, strengths, how to take, and more - Medical News Today, accessed May 23, 2025, https://www.medicalnewstoday.com/articles/drugs-rybelsus-dosage
101. WEGOVY (semaglutide) injection, for subcutaneous use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed May 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
102. Type 2 Diabetes Medicine | RYBELSUS® (semaglutide) tablets, accessed May 23, 2025, https://www.rybelsus.com/
103. accessed January 1, 1970, https://www.nejm.org/doi/full/10.1056/NEJMoa1901118
104. accessed January 1, 1970, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051
105. Rybelsus | European Medicines Agency (EMA), accessed May 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus
106. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, accessed May 23, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
107. FDA Issues Warning on Unapproved, Compounded GLP-1 Drugs for Weight Loss​ - Grand Health Partners, accessed May 23, 2025, https://grandhealthpartners.com/fda-issues-warning-on-unapproved-compounded-glp-1-drugs-for-weight-loss/
108. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, accessed May 23, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
109. A Review and Meta-Analysis of the Safety and Efficacy of Using ..., accessed May 23, 2025, https://www.mdpi.com/1648-9144/60/3/357
110. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial, accessed May 23, 2025, https://diabetesjournals.org/care/article/41/2/258/30310/Efficacy-and-Safety-of-Once-Weekly-Semaglutide
111. Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for ..., accessed May 23, 2025, https://pubmed.ncbi.nlm.nih.gov/39385875/
112. Comparative efficacy and safety of semaglutide 2.4 mg and ..., accessed May 23, 2025, https://pubmed.ncbi.nlm.nih.gov/40086043/
113. pubmed.ncbi.nlm.nih.gov, accessed May 23, 2025, https://pubmed.ncbi.nlm.nih.gov/40184508/#:~:text=Conclusion%3A%20Current%20literature%20supports%20tirzepatide,loss%20effects%20and%20safety%20profiles.
114. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes, accessed May 23, 2025, https://pubmed.ncbi.nlm.nih.gov/40184508/
115. World Obesity Day 2025: Recent Developments and the Road Ahead | Medpace, accessed May 23, 2025, https://www.medpace.com/blog/world-obesity-day-2025-recent-developments-and-the-road-ahead/
116. GLP-1 Receptor Agonist Market Size Surges 17.5% CAGR by 2034, accessed May 23, 2025, https://www.towardshealthcare.com/insights/glp-1-receptor-agonist-market-sizing
117. GLP-1 Market Industry Trends and Global Forecasts - GlobeNewswire, accessed May 23, 2025, https://www.globenewswire.com/news-release/2025/03/18/3044263/28124/en/GLP-1-Market-Industry-Trends-and-Global-Forecasts-2024-2035-Over-150-GLP-1-Drug-Candidates-in-Development-for-Multiple-Indications-Type-2-Diabetes-and-Obesity-Drive-GLP-1-Drug-Deve.html
118. Supply of Ozempic and other GLP-1 receptor agonists: Notice - Canada.ca, accessed May 23, 2025, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/information-consumers/supply-notices/ozempic.html
119. About the Ozempic (semaglutide) shortage | Therapeutic Goods Administration (TGA), accessed May 23, 2025, https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-ozempic-semaglutide-shortage
120. Ozempic (semaglutide) shortage 2022 - 2025 | Therapeutic Goods Administration (TGA), accessed May 23, 2025, https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/ozempic-semaglutide-shortage-2022-2025
121. Outlook for obesity in 2025: more than a transition year - IQVIA, accessed May 23, 2025, https://www.iqvia.com/locations/emea/blogs/2025/01/outlook-for-obesity-in-2025-more-than-a-transition-year
122. Study links Ozempic to kidney failure prevention - RACGP, accessed May 23, 2025, https://www1.racgp.org.au/newsgp/clinical/study-links-ozempic-to-kidney-failure-prevention
123. FDA Approves Ozempic for Type 2 Diabetes and Chronic Kidney Disease, accessed May 23, 2025, https://www.kidney.org/news-stories/fda-approves-ozempic-type-2-diabetes-and-chronic-kidney-disease
124. Regulatory Decision Summary for Ozempic - Drug and Health Products Portal, accessed May 23, 2025, https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS00626
125. accessed January 1, 1970, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637
126. FDA, EU Regulators Expand Indications for Semaglutide to Include Kidney Benefits for Patients With Diabetes in, accessed May 23, 2025, https://www.kidneynews.org/view/journals/kidney-news/17/3/article-p1_1.xml
127. Ozempic | European Medicines Agency (EMA), accessed May 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic
128. Health Canada accepts semaglutide 2.4 mg, a GLP-1RA treatment for MASH, as a supplemental New Drug Submission under the Priority Review Policy - BioSpace, accessed May 23, 2025, https://www.biospace.com/press-releases/health-canada-accepts-semaglutide-2-4-mg-a-glp-1ra-treatment-for-mash-as-a-supplemental-new-drug-submission-under-the-priority-review-policy
129. Regulatory Decision Summary for Ozempic - Drug and Health Products Portal, accessed May 23, 2025, https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS00317
130. Cardiovascular Disease | Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, accessed May 23, 2025, https://www.novomedlink.com/diabetes/products/treatments/ozempic/type-2-diabetes-and-cardiovascular-disease.html
131. Search criteria - Drug Product Database online query - Canada.ca, accessed May 23, 2025, https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
132. www.novonordisk.ca, accessed May 23, 2025, https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/ozempic-product-monograph.pdf
133. Report on the Deliberation Results February 6, 2023 Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental - PMDA, accessed May 23, 2025, https://www.pmda.go.jp/files/000265142.pdf
134. Concordance Between Pharmaceuticals and Medical Devices Agency Review and Ministry of Health, Labour and Welfare Decision Among New Drug Applications in Japan, accessed May 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11739745/
135. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight, accessed May 23, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
136. List of Approved Products - PMDA, accessed May 23, 2025, https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html
137. Ozempic isnt approved for weight loss in Australia So how are people accessing it - The University of Sydney, accessed May 23, 2025, https://www.sydney.edu.au/news-opinion/news/2024/04/04/ozempic-isnt-approved-for-weight-loss-in-australia-so-how-are-pe.html
138. Semaglutide approved for cardiovascular disease - Medical Republic, accessed May 23, 2025, https://www.medicalrepublic.com.au/semaglutide-approved-for-cardiovascular-disease/114505
139. New Indication Alert: FDA Approves Novo Nordisk's Ozempic® for Kidney Disease, accessed May 23, 2025, https://www.pearceip.law/2025/01/28/new-indication-alert-fda-approves-novo-nordisks-ozempic-for-kidney-disease/
140. accessed January 1, 1970, https://www.tga.gov.au/australian-register-therapeutic-goods
141. Rybelsus (semaglutide) FDA Approval History - Drugs.com, accessed May 23, 2025, https://www.drugs.com/history/rybelsus.html
142. Rybelsus 3 mg - Summary of Product Characteristics (SmPC) - (emc) | 11507, accessed May 23, 2025, https://www.medicines.org.uk/emc/product/11507/smpc
143. Human medicines European public assessment report (EPAR): Rybelsus, semaglutide, Date of authorisation: 03/04/2020, Revision: 13, Status, accessed May 23, 2025, https://efim.org/node/141859
144. Product information - Canada.ca, accessed May 23, 2025, https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98742
145. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes, accessed May 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9153832/
146. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials, accessed May 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9293331/
147. Rybelsus® approved in Japan for the treatment of type 2 diabetes - GlobeNewswire, accessed May 23, 2025, https://www.globenewswire.com/news-release/2020/06/29/2054428/0/en/Rybelsus-approved-in-Japan-for-the-treatment-of-type-2-diabetes.html
148. Profile of People Initiating Oral Semaglutide for the Treatment of Type 2 Diabetes in Japan:, accessed May 23, 2025, https://www.shinryo-to-shinyaku.com/db/pdf/sin_0060_05_0273.pdf
149. Australian public assessment report for Rybelsus - Therapeutic Goods Administration (TGA), accessed May 23, 2025, https://www.tga.gov.au/sites/default/files/2022-11/auspar-rybelsus-20221027.pdf
150. Rybelsus | Therapeutic Goods Administration (TGA), accessed May 23, 2025, https://www.tga.gov.au/resources/auspmd/rybelsus
151. Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease a - American Society for Preventive Cardiology, accessed May 23, 2025, https://www.aspconline.org/news/wegovy-receives-fda-approval-for-cardiovascular-risk-reduction-in-adults-with-known-heart-disease-a
152. Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease - Novo Nordisk, accessed May 23, 2025, https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167030
153. Outcome of assessment to extend the use of Wegovy (semaglutide) - European Medicines Agency, accessed May 23, 2025, https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-outcome-assessment-extend-use-wegovy-semaglutide_en.pdf
154. accessed January 1, 1970, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256
155. Human medicines European public assessment report (EPAR): Wegovy, semaglutide, Date of authorisation: 06/01/2022, Revision: 11, Status, accessed May 23, 2025, https://efim.org/node/141858
156. Wegovy | European Medicines Agency (EMA), accessed May 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
157. Wegovy Commercial Availability V2 - Obesity Canada, accessed May 23, 2025, https://obesitycanada.ca/wp-content/uploads/2024/05/wegovy-commercial-availability-press-release-en-may-2-24-v2-1.pdf
158. Table 1, Submitted for Review - Semaglutide (Wegovy) - NCBI Bookshelf, accessed May 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK601688/table/tr82698683820725_ch01_t01/?report=objectonly
159. Wegovy approved for lowered risk of heart attack: What it means for people living with obesity and heart disease - Healthing, accessed May 23, 2025, https://www.healthing.ca/obesity/wegovy-approved-for-lowered-risk-of-heart-attack-what-it-means-for-people-living-with-obesity-and-heart-disease
160. Health Canada approves Wegovy® (semaglutide injection) to reduce the risk of non-fatal myocardial infarction - BioSpace, accessed May 23, 2025, https://www.biospace.com/press-releases/health-canada-approves-wegovy-semaglutide-injection-to-reduce-the-risk-of-non-fatal-myocardial-infarction
161. The Multi-Sector Impacts of GLP-1RA Drugs - Teneo, accessed May 23, 2025, https://www.teneo.com/app/uploads/2024/03/Navigating-the-impacts-of-GLP-1RA-drugs-3.8.24.pdf
162. TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy - BioSpace, accessed May 23, 2025, https://www.biospace.com/press-releases/tivdak-tisotumab-vedotin-approved-by-japan-ministry-of-health-labour-and-welfare-for-the-treatment-of-advanced-or-recurrent-cervical-cancer-that-has-progressed-on-or-after-chemotherapy
163. Wegovy approved for cutting cardiovascular disease risk - RACGP, accessed May 23, 2025, https://www1.racgp.org.au/newsgp/clinical/wegovy-approved-for-cardiovascular-disease-in-over
164. 'Groundbreaking': TGA approves weight loss drug for CVD - Retail Pharmacy Magazine, accessed May 23, 2025, https://retailpharmacymagazine.com.au/groundbreaking-tga-approves-weight-loss-drug-for-cvd/